Global health functional food contract development and manufacturing (CDMO) corporations Sirio Pharma is stepping up its push into the Korean market.
Sirio Pharma said on the 14th that it has set a goal of establishing a Korea branch in 2026 and appointed Jeong Won-sun (photo) as head of business development for Korea and Japan. The move is part of the company's global expansion strategy to cultivate the Asia-Pacific market as a strategic core region alongside North America and Europe.
Since its founding in 1993 in Shantou, Guangdong Province, China, Sirio Pharma has posted steady growth. It currently operates seven production bases—four in China, two in California in the United States, and one in Germany—and has five research and development (R&D) centers: three in China including Shanghai, and one each in the United States and Germany.
Sirio Pharma has built competitiveness in the global market by leading with product lines such as vegan softgels and gummies (jellies). As of 2024, the company's revenue is about 900 billion won, and it has around 2,700 employees.
It has entered more than 50 countries worldwide, including China, the United States, Europe, and Australia. Head Jeong will lead the establishment of the Korea branch and plans to push ahead with ▲ analysis of Korean market trends ▲ securing distribution networks ▲ identifying M&A opportunities.
A Sirio Pharma official said, "The Korean health functional food market is an attractive market that grows more than 7% annually," adding, "In particular, with the K-food craze, Korea is an important base not only in the Asia-Pacific but also in the global market."